These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17618911)

  • 1. Alpha tumor necrosis factor contributes to CD8(+) T cell survival in the transition phase.
    Shi M; Ye Z; Umeshappa KS; Moyana T; Xiang J
    Biochem Biophys Res Commun; 2007 Aug; 360(3):702-7. PubMed ID: 17618911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LFA-1 defect-induced effector/memory CD8+ T cell apoptosis is mediated via Bcl-2/Caspase pathways and associated with downregulation of CD27 and IL-15R.
    Ye Z; Shi M; Xu S; Xiang J
    Mol Immunol; 2010 Aug; 47(14):2411-21. PubMed ID: 20569988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
    Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation.
    Sepulveda H; Cerwenka A; Morgan T; Dutton RW
    J Immunol; 1999 Aug; 163(3):1133-42. PubMed ID: 10415007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
    Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses.
    Xiao Z; Curtsinger JM; Prlic M; Jameson SC; Mescher MF
    Int Immunol; 2007 Jun; 19(6):733-43. PubMed ID: 17545279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effector T-cell differentiation during viral and bacterial infections: Role of direct IL-12 signals for cell fate decision of CD8(+) T cells.
    Keppler SJ; Theil K; Vucikuja S; Aichele P
    Eur J Immunol; 2009 Jul; 39(7):1774-83. PubMed ID: 19548244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections.
    Bachmann MF; Wolint P; Walton S; Schwarz K; Oxenius A
    Eur J Immunol; 2007 Jun; 37(6):1502-12. PubMed ID: 17492805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo.
    Dolfi DV; Duttagupta PA; Boesteanu AC; Mueller YM; Oliai CH; Borowski AB; Katsikis PD
    J Immunol; 2011 Apr; 186(8):4599-608. PubMed ID: 21389258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
    Rolle CE; Carrio R; Malek TR
    Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
    Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
    J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells.
    Apte SH; Baz A; Groves P; Kelso A; Kienzle N
    Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17475-80. PubMed ID: 18988742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T regulatory cells use a novel genetic program that includes CD103 to suppress Th1 immunity in eye-derived tolerance.
    Keino H; Masli S; Sasaki S; Streilein JW; Stein-Streilein J
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1533-42. PubMed ID: 16565389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin.
    Hegel JK; Knieke K; Kolar P; Reiner SL; Brunner-Weinzierl MC
    Eur J Immunol; 2009 Mar; 39(3):883-93. PubMed ID: 19224637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44high memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production.
    Wong KL; Tang LF; Lew FC; Wong HS; Chua YL; MacAry PA; Kemeny DM
    J Immunol; 2009 Jul; 183(1):41-50. PubMed ID: 19535645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic changes induced by IL-12 priming regulate effector and memory CD8 T cell differentiation.
    Lee JB; Lee KA; Chang J
    Int Immunol; 2007 Sep; 19(9):1039-48. PubMed ID: 17823312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.
    Kim EY; Teh SJ; Yang J; Chow MT; Teh HS
    J Immunol; 2009 Nov; 183(10):6051-7. PubMed ID: 19841176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H1 on hepatocytes facilitates priming of specific CD8 T cells but limits the specific recall of primed responses.
    Wahl C; Bochtler P; Chen L; Schirmbeck R; Reimann J
    Gastroenterology; 2008 Sep; 135(3):980-8. PubMed ID: 18621049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.